Claim OwnershipBeyond Biotech - the podcast from Labiotech
Subscribed: 132Played: 2,176
Subscribe
© 2025 Beyond Biotech - the podcast from Labiotech
Description
Welcome to the official Labiotech.eu podcast - Beyond Biotech! Each week, we talk about what's happening in the world of biotech, with news and interviews with experts from companies around the world. Join us as we cover the latest news, breakthroughs and innovations shaping the life sciences industry.A new podcast episode is available every Friday. The host is Dylan Kissane.
172 Episodes
Reverse
Urinary Tract infections, or UTIs, affect millions worldwide, driving sepsis, antibiotic overuse, and microbial resistance. Current diagnostics rely on either slow lab cultures or unreliable dipsticks, and often lead to delayed or unnecessary treatment. Llusern’s Lodestar DX changes that: a point-of-care test that detects 96% of key UTI pathogens in just 35 minutes, no lab required. In this episode I’m joined by Emma Hayhurst who shares her journey into diagnostics, Llusern’s mission, and the...
Today, I’m joined by Héctor García Martín, a Staff Scientist at Lawrence Berkeley National Laboratory. A pioneer in metabolic engineering and computational biology, Héctor has spent over a decade decoding microbial systems, everything from termite guts to genome-scale flux models, to unlock sustainable biomanufacturing. Now, he’s leading the charge in self-driving labs: AI-powered, robotic systems that automate experiments, predict biological behavior, and accelerate the design of microbes th...
Today we’re diving into the world of expression systems with Iskandar Dib, of Validogen and we’ll explore the remarkable potential of Pichia pastoris, a methylotrophic yeast that’s revolutionizing pharmaceutical protein production and beyond. From industrial enzymes to biomaterials, food, feed, and diagnostics, Pichia offers a reliable, scalable, and cost-efficient platform for recombinant protein expression. Iskandar explains how biotechs can unlock Pichia’s full potential throug...
In today's episode, we welcome Clarke Futch, Chairman and CEO of HealthCare Royalty Partners, or HCRx. HCRx are pioneers in royalty-based financing, with a thirty year track record in biopharma investing. Clarke has led more than 60 royalty acquisitions totaling nearly $4 billion and raised over $8 billion across various vehicles, executing more than 165 transactions that have fueled breakthroughs in life sciences. In this interview we examine the evolution of alternative funding models, the ...
When it comes to contraception, most of the innovation in the last century has focused on providing contraceptive alternatives for women. The contraceptive pill was approved by the FDA in 1960, the first IUD approved in 1968, and the female condom in 1993. For men, however, there has been little advancement since the invention of the rubber condom in 1855 and the first vasectomies in humans around the turn of the 20th century. Contraline is a biotechnology company that is aiming to change tha...
Raising money in the gene therapy space can be tough right now but, for the right company and with the right team, there is still cash to be found. But how do you connect with investors, how do you get your science in front of the right people, and how do you move from ‘I’m interested’ to ‘I’m signing on the dotted line’? This week I talk with Gerard Caelles, Chief Business Office of Splice Bio, a company that just closed a $135 million series B fundraising round. I quiz him on the practical ...
Immunology and inflammation are hot topics in biotech and biopharma, and innovations are emerging that can change the game for patients suffering from autoimmune, gastrointestinal, and metabolic disease. For top pharma companies, identifying these innovations early is essential and, for university labs, spinouts and startups, getting their science in front of the right industry partners is key. So how does science meet industry, and how can top pharma and venture investors find the next block...
Partnering conferences are where many deals in the biotech industry get made. With investors and top pharma companies on hand to meet with founders, learn about new science, and put money on the table for promising biotech, it’s little wonder that the biggest partnering events attract hundreds of innovators and thousands of attendees. One of the largest industry partnering events in Europe is BIOSPAIN. This year BIOSPAIN will take place in Barcelona, and the Catalan city will welcome particip...
How can you guarantee that top pharma will be interested in investing in your biotech startup? How can you be sure that the target you are focused on will be attractive to industry partners? And can AI help drive this interest and deliver these partnerships? These are questions that this week’s guest, Mati Gill, CEO of AION Labs in Israel, is perfectly positioned to answer. AION Labs has an innovative company creation process that empowers scientists and startups to tackle high-impact pharma ...
Lonza is one of the world’s largest contract development and manufacturing organizations (CDMOs), dedicated to serving the healthcare industry. They work alongside a broad range of customers – from emerging biotechs to top global pharmaceutical companies – to transform therapeutic discoveries into life-saving and life-enhancing treatments for their patients. Founded in 1897 in the Swiss Alps, Lonza has embraced innovation and kept pace with a fast-changing world for more than 125 years....
Parkinsons disease impacts some 10 million people worldwide and current approaches to treating the condition almost exclusively focus on addressing symptoms – there is, as of yet, no cure. One Finnish biotech, however, is not focused on alleviating symptoms but on modifying the course of the disease itself. Their hope is to be able to stop and even reverseneurodegenerative diseases like Parkinsons, and they have the backing of significant players, such as the Michael J Fox Foundation, to do j...
RNAi has changed the way that rare diseases are treated - is it about to do the same for more common conditions? Alnylam was the very first company to translate RNAi from Nobel Prize winning science into a commercially scalable platform. Founded in 2002, the company today has five different RNAi therapies on the market and a pipeline that continues to expand. While their early focus was on rare disease, today they are expanding into more common conditions, partnering with top pharma companies...
Nearly 1 billion people around the world suffer from mental health disorders, with the global economic cost of those disorders expected to reach $6 trillion by 2030. One of the most common of those mental health disorders is depressive disorder, commonly called depression, with some 280 million people suffering from either mild, moderate or severe depression. Conventional treatments for depression such as selective serotonin reuptake inhibitors, or SSRIs, can work for many people but fo...
The UK is preparing to change the game for healthcare - but why, how, and what will it cost? Recently the UK government announced plans to sequence the DNA of every baby born in that country. A part of the country’s 10 Year Health Plan, the program aims to identify rare genetic diseases early, prevent harms from delayed treatment and reduce future healthcare costs for the NHS. Yet along with those potential upsides come a range of ethical and practical questions, too: who guards the sequenced...
Is cultivated meat the future of pet food? And is there a place for cultivated meat on human dinner tables, too? Traditional agricultural methods are slow, require large tracts of land, significant energy and environmental inputs, and – somewhat obviously – the slaughter of hundreds of millions of animals every year. Cultivated meat – that is meat that is grown in a lab – requires little land, less energy, and in the case of Meatly, nothing more than a single cell from a single chicken egg, o...
With supply chain management and optimization, risk management, and the capacity to address global markets efficiently and effectively top of mind for all growing biotechs, I'm excited to be joined by Alison Pritchard, Vice President, Business Development at Cryoport Systems, to learn more about how they support life science innovators worldwide. Cryoport Systems evolved alongside the life science industry and expanded its capabilities into full-scale supply chain management solutions t...
Inflammatory diseases involve excessive or ongoing inflammation that damages tissues and affects many different human systems, including digestion, immunity, circulation, breathing, and the nervous system. The demand for anti-inflammatory treatments is growing quickly and is tipped to top a quarter of a trillion dollars within the decade as cases increase and new approaches to address inflammation emerge. This week, I had the chance to talk to Niels Riedemann, CEO and Founder of InflaRx, abou...
Ros Deegan is an industry leader and the CEO of OMass Therapeutics, an Oxford-based biotechnology company discovering medicines against highly-validated target ecosystems, such as membrane proteins or intracellular complexes. OMass’s MC2 program targeting Congenital Adrenal Hyperplasia, or CAH, is set to enter the clinic this year and in our interview today she walks me through how the company is preparing for their trials, how their approach differs to existing treatment options, and ...
The World Health Organization reports that more than 600 million people suffer from lower back pain globally, making it the leading cause of disability worldwide. Chronic lower back pain – where the pain persists for more than 3 months – develops in between 5 and 10% of all lower back pain cases, with life-altering impacts for patients. And that’s where today’s guest, Steve Ruston, of Persica Pharmaceuticals comes in. Persica is developing a groundbreaking and transformative treatment f...
Trauma surgeons in Ukraine operating theaters saved lives and limbs thanks to the innovative lab-grown blood vessels from US biotech, Humacyte. Humacyte is pioneering a platform that enables the investigation, development, and manufacture of bioengineered human tissues and organs that are designed to be universally implantable, off-the-shelf, and regenerative, with the goal of treating a wide variety of diseases, injuries, and chronic conditions. This week I had the chance to speak to Humacyt...
Comments
Download from Google Play
Download from App Store
United States